Although scientists have long known about the important role of serotonin in the development of cancer, underlying this mechanisms were still unknown. Now the team from Switzerland managed not only to determine them, but also to achieve impressive results of the use of SSRS in the treatment of cancer.
Neurotransmitter serotonin, which is also called hormone of happiness, is usually reduced in people with depression. In addition to regulating the mood, serotonin also affects many other features of the body. So, most of it is not in the brain, but is stored in blood platelets. Selective selection inhibitors of serotonin (SSRS) inhibitors used in the treatment of depression increase the level of hormone in the brain and reduce blood.
New research teams from Zurich University
Scientists have established that cancer cells use serotonin to produce a PD-L1 molecule, which binds to T-killers and disrupts their function. As a result of this interaction, cancer can be formed to form favorable conditions for growth and avoid the attacks of the immune system. SIRES and other similar drugs destroy this mechanism.
It is known that PD-L1 is also a target for immunotherapy, so scientists decided to test the effect of antidepressants in combination with inhibitors of immune checkpoints.
«We see that the medications already approved for humans can improve the therapy of the incurable pancreatic cancer and colorectal cancer,» the author of Pierre Allen Claus commented on the author. For example, five-year survival at the pancreatic tumor is less than 5-10%.
Now scientists are preparing to conduct clinical studies. If successful therapy becomes the long-awaited hope for hundreds of thousands of patients.
Earlier, another group of researchers has demonstrated that the use of antidepressant from the SSIOS group
We still have